Navigation Links
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/11/2011

NEW YORK, Nov. 11, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference, being held at the Pierre Hotel in New York City. Mr. Bentsur's presentation is scheduled to take place on Wednesday, November 16, 2011, at 9:00 a.m. ET.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevat
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
7. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
8. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
11. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... signal a positive sign for the economy , PLYMOUTH ... ( www.ecri.org ), an independent nonprofit that ... offers procurement support to more than 2,000 U.S. hospitals, ... for medical technology acquisition support, a strong signal that ...
... MONMOUTH JUNCTION, N.J., Oct. 19 Transave Inc., today ... investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic ... latest results along with previously reported data demonstrate significant ... in two indications - for the treatment of lung ...
Cached Medicine Technology:ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5
(Date:4/24/2014)... negative and stressful outcomes for parents who have a ... illness, says a recent study led by a researcher ... are numerous and life-changing and stress levels high, the ... research reported positive outcomes as well, a phenomenon known ... recent issue of the American Journal of Orthopsychiatry ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... CHAMPAIGN, Ill. It is better to give than to ... enjoy giving, a new study suggests. , The study found ... such as giving their money to family members, are less ... thrill from taking risks or keeping the money for themselves. ... of the National Academy of Sciences . , The study ...
(Date:4/24/2014)... virus caused the first flu pandemic in the 21st ... killed more than 50 people in the country. Since ... epidemics (winter/spring seasons). , Infections with influenza pH1N1 ... Health Organization has recommended Tamiflu for treatment of patients ... drug is that it targets viral proteins which mutate ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... , ... Juniper Research’s Mobile Health Opportunities Report, public and private healthcare providers will be able ... of remote patient monitoring using cellular networks by the year 2014. , ... Hampshire, UK (PRWEB) May ...
... Capture ... and tackle complex medical billing issues. , ... Washington, DC (Vocus) May 11, 2010 -- Capture Billing and Consulting, Inc. ... medical practices come together, ask questions and help each other. Over the past decade ...
... Edgy ... ... Is the primitive fear of being caught naked causing countless women to quit breastfeeding each ... to the public conversation about breastfeeding in an edgy new internet campaign that is taking ...
... ... to Dentists , ... Dallas, TX (PRWEB) May 10, 2010 -- Bold Ventures, a diversified holding company ... launched a new services company for the dental industry. The company, Dental Wealth Partners, will ...
... comes from microscopic contaminants from fuel combustion, report says ... proof that air pollution is associated with heart attack, ... Association (AHA) scientific statement released Monday. , Of the ... for fine particulate matter (called PM2.5 by scientists because ...
... study shows , MONDAY, May 10 (HealthDay News) -- Siblings ... are also more likely to suffer from the condition, a ... is published in the May issue of Archives of ... condition for both physicians and patients. , "These authors found ...
Cached Medicine News:Health News:Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research 2Health News:Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research 3Health News:Capture Medical Billing Launches Facebook Fan Page to Help Improve Medical Billing Issues 2Health News:Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates? 2Health News:Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates? 3Health News:Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates? 4Health News:Bold Ventures Launches New Healthcare Business 2Health News:Bold Ventures Launches New Healthcare Business 3Health News:Bold Ventures Launches New Healthcare Business 4Health News:Air Pollution Raises Risk of Heart Disease, Death 2Health News:Restless Legs Syndrome Can Have Family Ties 2
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: